ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,370.33
0.00%
Dow Jones
39,671.04
-0.51%
Gold vs US Dollar
2,366.82
-0.63%
Brent Oil
81.475
-0.07%
Bitcoin
69,469.36
0.54%
Pepperstone
Advertisement
Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Nurix Therapeutics Inc (NRIX) Share Price

NRIX Nurix Therapeutics Inc

16.11
0.17 (1.07%)
23 May 2024 - Closed
Delayed by 15 minutes
 Name  Symbol  Market  Type  ISIN  Description 
 Nurix Therapeutics Inc NASDAQ:NRIX NASDAQ Common Stock  
     Change  % Chg  Cur  Bid  Offer  High  Low  Open  Volume  Chg Time
Upgrade Icon
 		 RN  NRN 
   0.17 1.07 16.11 10.25 16.89 16.82 15.80 15.86 2,009,146 00:00:00   
 Sector  Turnover  Profit  EPS - Basic  PE ratio  Mkt Cap 
 Pharmaceutical Preparations 76.99M -143.95M -2.9441 -5.48 788.17M
 Type  Size  Price  Time  Units 
 16 516 16.11 20:01:31 USD
 
Pre-Market and After-Hours
Recent News
DateTimeSource
HeadlineMore NRIX News
21/05/202412:06EDGAR2Form 8-K - Current report
21/05/202400:25EDGAR2Form 4 - Statement of changes in beneficial ownership of securities
21/05/202400:25EDGAR2Form 4 - Statement of changes in beneficial ownership of securities
20/05/202421:00GLOBENurix Therapeutics Announces Board Chair Transition
14/05/202415:00GLOBENurix Therapeutics Announces Upcoming Oral Presentation of New Data from Ongoing Clinical Trial of NX-5948, a Selective Bruton’s Tyrosine Kinase (BTK) Degrader, at the European Hematology Association Congress (EHA2024)
07/05/202412:00GLOBENurix Therapeutics to Participate in RBC Capital Markets Global Healthcare Conference
16/04/202423:21GLOBENurix Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Period
Draw mode
Data Downloads for NRIX

Export historical price information open, high, low, close, volume (OHLCV) to Excel

Intraday price data (2 weeks, 1 minute bars)


Loading Follow Feed...

Latest Nurix Therapeutics Inc Articles